116 related articles for article (PubMed ID: 22611950)
1. Clinical significance of serum growth-regulated oncogene alpha (GROalpha) in patients with gynecological cancer.
Nishikawa R; Suzumori N; Nishiyama T; Nishikawa H; Arakawa A; Sugiura-Ogasawara M
Eur J Gynaecol Oncol; 2012; 33(2):138-41. PubMed ID: 22611950
[TBL] [Abstract][Full Text] [Related]
2. High expression of insulin-like growth factor binding protein-2 messenger RNA in epithelial ovarian cancers produces elevated preoperative serum levels.
Lancaster JM; Sayer RA; Blanchette C; Calingaert B; Konidari I; Gray J; Schildkraut J; Schomberg DW; Marks JR; Berchuck A
Int J Gynecol Cancer; 2006; 16(4):1529-35. PubMed ID: 16884361
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of circulating tumor necrosis factor-alpha in patients with gynecological malignancies.
De Jaco P; Asselain B; Orlandi C; Fridman WH; Teillaud JL
Int J Cancer; 1991 May; 48(3):375-8. PubMed ID: 2040531
[TBL] [Abstract][Full Text] [Related]
4. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
5. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
Odunsi K; Wollman RM; Ambrosone CB; Hutson A; McCann SE; Tammela J; Geisler JP; Miller G; Sellers T; Cliby W; Qian F; Keitz B; Intengan M; Lele S; Alderfer JL
Int J Cancer; 2005 Feb; 113(5):782-8. PubMed ID: 15499633
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of serum Dkk-3 in patients with gynecological cancer.
Jiang T; Huang L; Wang S; Zhang S
J Obstet Gynaecol Res; 2010 Aug; 36(4):769-73. PubMed ID: 20666943
[TBL] [Abstract][Full Text] [Related]
7. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
8. Expression of serum miR-200a, miR-200b, and miR-200c as candidate biomarkers in epithelial ovarian cancer and their association with clinicopathological features.
Zuberi M; Mir R; Das J; Ahmad I; Javid J; Yadav P; Masroor M; Ahmad S; Ray PC; Saxena A
Clin Transl Oncol; 2015 Oct; 17(10):779-87. PubMed ID: 26063644
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of epidermal growth factor, transforming growth factor, and c-erbB2 in ovarian cancer.
Balcan E; Demirkiran F; Aydin Y; Sanioglu C; Bese T; Arvas M; Akçay T; Cift T
Int J Gynecol Cancer; 2012 Sep; 22(7):1138-42. PubMed ID: 22914212
[TBL] [Abstract][Full Text] [Related]
10. Sperm-associated antigen 9 is a promising marker for early diagnosis of endometrial cancer.
Baser E; Togrul C; Ozgu E; Ayhan S; Caglar M; Erkaya S; Gungor T
Asian Pac J Cancer Prev; 2013; 14(12):7635-8. PubMed ID: 24460345
[TBL] [Abstract][Full Text] [Related]
11. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
13. A serum based analysis of ovarian epithelial tumorigenesis.
Nolen B; Marrangoni A; Velikokhatnaya L; Prosser D; Winans M; Gorelik E; Lokshin A
Gynecol Oncol; 2009 Jan; 112(1):47-54. PubMed ID: 19007974
[TBL] [Abstract][Full Text] [Related]
14. [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].
Kondera-Anasz Z; Mielczarek-Palacz A; Switała J
Ginekol Pol; 2003 Sep; 74(9):761-6. PubMed ID: 14674121
[TBL] [Abstract][Full Text] [Related]
15. [Clinical validation of multiple biomarkers suspension array technology for ovarian cancer].
Zhao BB; Yang ZJ; Wang Q; Pan ZM; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2017 Jan; 52(1):11-19. PubMed ID: 28190310
[No Abstract] [Full Text] [Related]
16. Validation and characterization of human kallikrein 11 as a serum marker for diagnosis of ovarian carcinoma.
McIntosh MW; Liu Y; Drescher C; Urban N; Diamandis EP
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4422-8. PubMed ID: 17671125
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of Tissue Factor Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell Carcinoma.
Arakawa N; Kobayashi H; Yonemoto N; Masuishi Y; Ino Y; Shigetomi H; Furukawa N; Ohtake N; Miyagi Y; Hirahara F; Hirano H; Miyagi E
PLoS One; 2016; 11(10):e0165609. PubMed ID: 27798689
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
19. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic performance of the biomarkers HE4 and CA125 in type I and type II epithelial ovarian cancer.
Kristjansdottir B; Levan K; Partheen K; Sundfeldt K
Gynecol Oncol; 2013 Oct; 131(1):52-8. PubMed ID: 23891789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
